Carl J. Pepine, MD
Carl J. Pepine, MD, is Professor of Medicine, Division of Cardiovascular Medicine at the University of Florida College of Medicine in Gainesville, Florida. He is Division Director Emeritus and Eminent Scholar Emeritus.
|BS||University of Pittsburgh||Pre-Medical|
|MD||New Jersey Medical School|
|Residency||Jefferson Medical College Hospital
Regional Naval Medical Center
|Fellowship||Regional Naval Medical Center and Jefferson Medical College Hospital||Cardiopulmonary Physiology and Cardiovascular Medicine|
Dr. Pepine is an internationally recognized leader in both the clinical and scientific areas of cardiovascular medicine. His major interests focus on the pathophysiology of ischemic heart disease and coronary and systemic vascular hemodynamic mechanisms underlying the disease. He is principal investigator for the UF center for the NHLBI-funded Women’s Ischemia Syndrome Evaluation (WISE) and the UF center for the Cardiovascular Cell Therapy Research Network (CCTRN). He has been or is the PI for many investigator initiated clinical trials, as well as NHLBI trials. He is past president of the American College of Cardiology (ACC), the national professional organization for cardiovascular specialists. He currently serves on the Board of Trustees of the ACC and many committees and task forces and is the founder and overall Project Chair for the Vascular Biology Working Group (VBWG).
Dr. Pepine’s clinical interests include Ischemic heart disease, heart disease in women, cardiovascular cell therapy, preventive cardiology, genetic cardiology, clinical trials in cardiovascular disease, and hypertension & lipid disorders.
Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57:2037-114.
Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forciea MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011;123:2434-506.
Cooper-DeHoff RM, Egelund EF, Pepine CJ. Blood pressure lowering in patients with diabetes–one level might not fit all. Nat Rev Cardiol. 2011;8:42-9. PMC3016088
Goldberg AC, Bittner V, Pepine CJ, Kelly MT, Thakker K, Setze CM, Lele A, Sleep DJ. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia. Am J Cardiol. 2011;107:898-905.
Gong Y, Beitelshees AL, Cooper-DeHoff RM, Lobmeyer MT, Langaee TY, Wu J, Cresci S, Province MA, Spertus JA, Pepine CJ, Johnson JA. Chromosome 9p21 haplotypes and prognosis in white and black patients with coronary artery disease. Circ Cardiovasc Genet. 2011;4:169-78. PMC3101633
Lobmeyer MT, Wang L, Zineh I, Turner ST, Gums JG, Chapman AB, Cooper-DeHoff RM, Beitelshees AL, Bailey KR, Boerwinkle E, Pepine CJ, Johnson JA. Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics. 2011;21:42-9. PMC3028503
Petersen JW, Forder JR, Thomas JD, Moye LA, Lawson M, Loghin C, Traverse JH, Baraniuk S, Silva G, Pepine CJ. Quantification of Myocardial Segmental Function in Acute and Chronic Ischemic Heart Disease and Implications for Cardiovascular Cell Therapy Trials A Review From the NHLBI-Cardiovascular Cell Therapy Research Network. JACC Cardiovasc Imaging. 2011;4:671-9.
Price ET, Pacanowski MA, Martin MA, Cooper-DeHoff RM, Pepine CJ, Zineh I, Johnson JA. Liver X receptor alpha gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. Pharmacogenet Genomics. 2011;21:333-40. PMC3093636
Shufelt CL, Johnson BD, Berga SL, Braunstein GD, Reis SE, Bittner V, Yang Y, Pepine CJ, Sharaf BL, Sopko G, Kelsey SF, Merz CN. Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation. Menopause. 2011.
Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, Lambers Heerspink HJ, Perkovic V, Huxley R, Arima H, Patel A, Chalmers J, Woodward M, MacMahon S, Neal B. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens. 2011;29:4-16. [Pepine]
Singh PP, Abbott JD, Lombardero MS, Sutton-Tyrrell K, Woodhead G, Venkitachalam L, Tsapatsaris NP, Piemonte TC, Lago RM, Rutter MK, Nesto RW. The prevalence and predictors of an abnormal ankle-brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Care. 2011;34:464-7. PMC3024368 [Pepine]
Tardif JC, L’Allier PL, Gregoire J, Ibrahim R, McFadden G, Kostuk W, Knudtson M, Labinaz M, Waksman R, Pepine CJ, Macaulay C, Guertin MC, Lucas A. A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2010;3:543-8.
Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Simpson LM, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Baraniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moye LA, Simari RD. LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J. 2010;37:412-20. PMC2929864
Willerson JT, Perin EC, Ellis SG, Pepine CJ, Henry TD, Zhao DX, Lai D, Penn MS, Byrne BJ, Silva G, Gee A, Traverse JH, Hatzopoulos AK, Forder JR, Martin D, Kronenberg M, Taylor DA, Cogle CR, Baraniuk S, Westbrook L, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moye LA, Simari RD. Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design. Am Heart J. 2010;160:215-23. PMC2921924
Rutledge T, Linke SE, Johnson BD, Bittner V, Krantz DS, Whittaker KS, Eastwood JA, Eteiba W, Cornell CE, Pepine CJ, Vido DA, Olson MB, Shaw LJ, Vaccarino V, Bairey Merz CN. Self-rated versus objective health indicators as predictors of major cardiovascular events: the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation. Psychosom Med. 2010;72:549-55. PMC3113514
Shufelt C, Bretsky P, Almeida CM, Johnson BD, Shaw LJ, Azziz R, Braunstein GD, Pepine CJ, Bittner V, Vido DA, Stanczyk FZ, Bairey Merz CN. DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health–National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab. 2010;95:4985-92. PMC2968728
Niu Y, Gong Y, Langaee TY, Davis HM, Elewa H, Beitelshees AL, Moss JI, Cooper-Dehoff RM, Pepine CJ, Johnson JA. Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). Circ Cardiovasc Genet. 2010;3:548-55. PMC3060561
Park KE, Pepine CJ. Pathophysiologic mechanisms linking impaired cardiovascular health and neurologic dysfunction: the year in review. Cleve Clin J Med. 2010;77 Suppl 3:S40-5.
Park KE, Pepine CJ. Bone marrow-derived cells and hypertension. Expert Rev Cardiovasc Ther. 2010;8:1139-48.
Pepine CJ, Jacobson TA, Carlson DM, Kelly MT, Setze CM, Gold A, Stolzenbach JC, Williams LA. Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies. Clin Cardiol. 2010;33:609-19.
Khuddus MA, Pepine CJ, Handberg EM, Bairey Merz CN, Sopko G, Bavry AA, Denardo SJ, McGorray SP, Smith KM, Sharaf BL, Nicholls SJ, Nissen SE, Anderson RD. An intravascular ultrasound analysis in women experiencing chest pain in the absence of obstructive coronary artery disease: a substudy from the National Heart, Lung and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Interv Cardiol. 2010;23:511-9. PMC3019081
Beitelshees AL, Johnson JA, Hames ML, Gong Y, Cooper-Dehoff RM, Wu J, Cresci S, Ma CX, Pepine CJ, Province MA, Spertus JA, McLeod HL. Aromatase gene polymorphisms are associated with survival among patients with cardiovascular disease in a sex-specific manner. PLoS One. 2010;5:e15180. PMC3000815
Bhatwadekar AD, Guerin EP, Jarajapu YP, Caballero S, Sheridan C, Kent D, Kennedy L, Lansang MC, Ruscetti FW, Pepine CJ, Higgins PJ, Bartelmez SH, Grant MB. Transient inhibition of transforming growth factor-beta1 in human diabetic CD34+ cells enhances vascular reparative functions. Diabetes. 2010;59:2010-9. PMC2911069
Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61-8. PMC3008411
Della Rocca DG, Pepine CJ. Endothelium as a predictor of adverse outcomes. Clin Cardiol. 2010;33:730-2.
Denardo SJ, Gong Y, Nichols WW, Messerli FH, Bavry AA, Cooper-Dehoff RM, Handberg EM, Champion A, Pepine CJ. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med. 2010;123:719-26. PMC3008373
Denardo SJ, Messerli FH, Gaxiola E, Aranda JM, Jr., Cooper-Dehoff RM, Handberg EM, Gong Y, Champion A, Zhou Q, Pepine CJ. Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). Am J Cardiol. 2010;106:498-503. PMC3005196
Doyle M, Weinberg N, Pohost GM, Bairey Merz CN, Shaw LJ, Sopko G, Fuisz A, Rogers WJ, Walsh EG, Johnson BD, Sharaf BL, Pepine CJ, Mankad S, Reis SE, Vido DA, Rayarao G, Bittner V, Tauxe L, Olson MB, Kelsey SF, Biederman RW. Prognostic value of global MR myocardial perfusion imaging in women with suspected myocardial ischemia and no obstructive coronary disease: results from the NHLBI-sponsored WISE (Women’s Ischemia Syndrome Evaluation) study. JACC Cardiovasc Imaging. 2010;3:1030-6.
Gee AP, Richman S, Durett A, McKenna D, Traverse J, Henry T, Fisk D, Pepine C, Bloom J, Willerson J, Prater K, Zhao D, Koc JR, Ellis S, Taylor D, Cogle C, Moye L, Simari R, Skarlatos S. Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience. Cytotherapy. 2010;12:684-91.
James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905-17. [Pepine]
Rutledge T, Linke SE, Johnson BD, Bittner V, Krantz DS, Whittaker KS, Eastwood JA, Eteiba W, Cornell CE, Pepine CJ, Vido DA, Olson MB, Shaw LJ, Vaccarino V, Bairey Merz CN. Self-rated versus objective health indicators as predictors of major cardiovascular events: The NHLBI-sponsored Women’s Ischemia Syndrome Evaluation. Psychosom Med. 2010;72:549-55.
Pepine CJ, Anderson RD, Sharaf BL, Reis SE, Smith KM, Handberg EM, Johnson BD, Sopko G, Bairey Merz CN. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia: results from the National Heart, Lung and Blood Institute WISE Study (Women’s Ischemia Syndrome Evaluation). J Am Coll Cardiol. 2010;55:2825-32.
Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61-8.
Bairey Merz CN, Olson MB, McClure C, Yang YC, Symons J, Sopko G, Kelsey SF, Handberg E, Johnson BD, Cooper-DeHoff RM, Sharaf B, Rogers WJ, Pepine CJ. A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: results from the National Institutes of Health/National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation (WISE). Am Heart J. 2010;159:987.e1-7.
Pepine CJ. Residual risk for secondary ischemic events in patients with atherothrombotic disease: opportunity for future improvements in patient care. Ann Med. 2010;42:19-35.
Eagle KA, Ginsburg GS, Musunru K, Aird WC, Balaban RS, Bennett SK, Blumenthal RS, Coughlin SR, Davidson KW, Frohlich ED, Greenland P, Jarvik GP, Libby P, Pepine CJ, Ruskin JN, Stillman AE, Van Eyk JE, Tolunay HE, McDonald CL, Smith SC Jr. Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions. Report of the National Heart, Lung and Blood Institute Working Group. Circulation. 2010;121:1447-54.
Simari RD, Moyé LA, Skarlatos SI, Ellis SG, Zhao DXM, Willerson JT, Henry TD, Pepine CJ. Development of a network to test strategies in cardiovascular cell delivery: The NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN). J Cardiovasc Transl Res. 2010;3:30-6.
Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-DeHoff RM, Handberg EM, Pepine CJ. Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INVEST trial. Hypertension. 2010;55:48-53.
Yan RT, Yan AT, Mahaffey KW, White HD, Pieper K, Sun JL, Pepine CJ, Biasucci LM, Gulba DC, Lopez-Sendon J, Goodman SG; on behalf of the SYNERGY Trial Investigators. Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2010;31:958-66.
BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-15. [Pepine]
Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA; CHAMPION PLATFORM Investigators. Intravenouos platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361:2330-41. [Pepine]
Cooper-DeHoff RM, Handberg EM, Mancia G, Zhou Q, Champion A, Legler UF, Pepine CJ. INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. Expert Rev Cardiovasc Ther. 2009;7:1329-40.
Rutledge T, Linke SE, Krantz DS, Johnson BD, Bittner V, Eastwood JA, Eteiba W, Pepine CJ, Vaccarino V, Francis J, Vido DA, Merz CN. Comorbid depression and anxiety symptoms as predictors of cardiovascular events: results from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) study. Psychosom Med. 2009;71:958-64.
Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Piller LB, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. Am Heart J. 2009;158:356-63.
Gong Y, Handberg E, Gerhard T, Cooper-DeHoff RM, Ried LD, Johnson JA, Pepine CJ; for the INVEST Investigators. Systolic blood pressure and subjective well-being in patients with coronary artery disease. Clin Cardiol. 2009; 32:627-32.
Beitelshees AL, Navare H, Wang D, Gong Y, Wessel J, Moss JI, Langaee TY, Cooper-DeHoff RM, Sadee W, Pepine CJ, Schork NJ, Johnson JA. CACNA1C Gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet. 2009;2:362-70.
Bairey Merz CN, Johnson BD, Berga SL, Braunstein GD, Azziz R, Yang Y, Reis SE, Bittner V, Hodgson TK, Pepine CJ, Sharaf BL, Sopko G, Kelsey SF. Total estrogen time and coronary disease in women: insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Women’s Health. 2009;18:1315-22.
Pepine CJ. The impact of nitric oxide in cardiovascular medicine: untapped potential utility. Am J Med. 2009;122(5A):S10-S15.
Cooper-DeHoff RM, Pacanowski MA, Pepine CJ. Cardiovascular therapies and associated glucose homeostasis. J Am Coll Cardiol. 2009;53 Suppl S:S28-S34.
Pepine CJ. Pleiotropic effects of ACE inhibitors. Medicographia. 2009;31:9-15.
Haller MJ, Stein JM, Shuster JJ, Theriaque D, Samyn MM, Pepine C, Silverstein JH. Pediatric Atorvastatin in Diabetes Trial (PADIT): A pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus. J Ped Endocrinol Metab. 2009; 22:65-8.
Please click here for a list of Dr. Pepine’s industry relationships.